DMC Biotechnologies, a player in the synthetic biology and precision fermentation sectors, has appointed Dr James (Jim) Flatt as its new CEO, effective immediately.

This leadership change comes as the company seeks to enhance its operational capabilities and expand its portfolio of sustainable ingredients and chemicals.

Flatt brings over 30 years of extensive experience in biotechnology and biomanufacturing to DMC. His previous roles include co-founder and CEO of Brightseed, where he spearheaded the Forager AI platform, facilitating the discovery and commercialisation of novel bioactive health ingredients. He has also held senior leadership positions at notable organisations such as Hampton Creek, Synthetic Genomics and Martek Biosciences.

The appointment is seen as a strategic move to guide DMC through its next growth phase, focusing on scaling operations and commercialising various nutraceutical ingredients.

“Jim is an exceptional leader with a significant track record of developing and commercialising innovative biotechnology-based products,” said Matt Lipscomb, founder and board member of DMC Biotechnologies. “I am confident in his ability to take DMC to new heights, and I look forward to supporting him in his new role.”

DMC Biotechnologies is recognised for its proprietary Dynamic Metabolic Control platform, which enhances fermentation processes for greater scalability and efficiency. The company aims to leverage this technology to produce a range of sustainable chemicals and ingredients that meet the evolving demands of the food and beverage industry.

Rob van der Meij, chairman of the board and managing partner of Capricorn Partners, added: “Jim’s deep expertise in leading teams and strong track record in commercialising numerous biotechnology-based products across multiple industries will be instrumental for DMC’s next commercial phase."

He continued: "Under his leadership, we will expand our operational capabilities and drive the launch of several new products leveraging DMC’s proprietary technology”.

Flatt holds a PhD in chemical engineering from the University of Wisconsin-Madison, along with degrees from MIT and UC Berkeley. He holds over a dozen patents and receiving multiple industry awards for his contributions to biotechnology.

In a statement regarding his new role, Flatt commented: “I am honoured to join DMC Biotechnologies as CEO. The company is uniquely positioned at the forefront of sustainable biomanufacturing, and I look forward to working with the talented team to scale our operations and commercialise impactful solutions that address critical challenges in global supply chains, health and the environment.”

#DMCBiotechnologies #appointments #precisionfermentation